Representative Image
BEIJING: Chinese COVID-19 vaccine candidate, CoronaVac, developed by Sinovac Biotech, triggered quick immune response in its late stage trails. However, the level of antibodies produced was lower than the people who already had COVID-19 before and had recovered. The researchers said that CoronaVac can provide sufficient protection from novel coronavirus infection based on their experience with other vaccines and preclinical trails.
CoronaVac and other Chinese vaccines are going through late stage trails to determine their effectiveness on COVID-19. Zhu Fegcai, one of the authors, said that the findings show that CoronaVac is capable of inducing a quick antibody response within four weeks of immunisation with two doses at an interval of 14 days.
Researchers said that the large last-stage trails will be important to determine the immune response generated by the CoronaVac vaccine. Sinovac vaccine is also in the Phase 3 trails in Indonesia, Brazil and Turkey.
Representative Image CHENNAI, Tamil Nadu: Intending to eradicate manual cleaning, the Madras High Court has…
Representative Image NEW DELHI: The Commission for Air Quality Management (CAQM) has urged the urban…
Representative Image TIRUCHI, Tamil Nadu: Villagers from the Pudukottai district and Manapparai near Tiruchi have…
Representative Image New Delhi: NetApp, a data infrastructure company, has released a report on cloud…
Representative Image CHENNAI, Tamil Nadu: Given the brewing heatwave conditions, the Government of Tamil Nadu…
Representative Image NEW DELHI: Elections for the posts of Mayor and Deputy Mayor of the Municipal Corporation of…